Kasture Sarang, Sakamuri Raj
Trauma and Orthopaedics, Liverpool University NHS Foundation Trust, Liverpool, GBR.
Trauma and Orthopaedics, Ysbyty Gwynedd, Bangor, GBR.
Cureus. 2021 Nov 27;13(11):e19952. doi: 10.7759/cureus.19952. eCollection 2021 Nov.
Introduction The use of collagenase injection as a minimally invasive procedure for correction of Dupuytren's deformity is well reported in the literature. We report our experience and long-term outcome of this procedure performed in a single secondary care centre. Methods We prospectively evaluated 143 fingers that underwent Dupuytren's deformity correction using CCH injection. Early side effects, degree of correction, recurrence, and patient-reported outcomes were noted. Results Early local complications were resolved in two weeks' duration. No major complications were encountered. More than 80% achieved immediate full correction of deformity and at an average follow-up of five years, 23% of patients had a recurrence. Around 92% were very satisfied with the procedure. Conclusion CCH is a safe and effective minimally invasive method to achieve correction of palmar Dupuytren's deformity and is associated with a high patient satisfaction rate.
引言 文献中已充分报道了使用胶原酶注射作为矫正掌腱膜挛缩症畸形的微创手术方法。我们报告了在单一二级医疗中心进行该手术的经验和长期结果。方法 我们前瞻性评估了143根接受胶原酶注射矫正掌腱膜挛缩症畸形的手指。记录早期副作用、矫正程度、复发情况以及患者报告的结果。结果 早期局部并发症在两周内得到解决。未出现重大并发症。超过80%的患者畸形立即得到完全矫正,平均随访五年时,23%的患者出现复发。约92%的患者对该手术非常满意。结论 胶原酶注射是一种安全有效的矫正掌部掌腱膜挛缩症畸形的微创手术方法,且患者满意度高。